SciClone Pharmaceuticals Inc (SCLN)

11.15
Prev Close 11.15
Day Low/High 11.15 / 11.20
52 Wk Low/High 8.55 / 11.43
Avg Volume 462.50K
Exchange
Shares Outstanding 52.19M
Market Cap 581.94M
EPS 0.60
Div & Yield N.A. (N.A)

Sino Clean Energy, Zale: Early Volume Plays

Several stocks trading near $5 were moving on above-average volume during Friday's session.

SciClone, IncrediMail: Midday Volume Plays

Several stocks trading near $5 were moving on above-average volume during Thursday's session.

E*Trade, Hanmi Financial: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Monday's session.

Micro Caps, Biotechs and Bonds

Micro Caps, Biotechs and Bonds

Guests include Michael Corbett, fund manager for the Corbett Micro Cap Opportunities fund, Marilyn Cohen, author of "Bonds Now!" and TheStreet.com's Stocks Under $10 portfolio manager David Peltier.

YRC Worldwide, Netlist: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Tuesday's session.

Achillon, Cyclacel: Early Volume Plays

Achillon, Cyclacel: Early Volume Plays

Several stocks trading under $5 were poised to move on above-average volume during Monday's session.

SciClone: Pump Up the Volume

SciClone: Pump Up the Volume

SciClone Pharmaceuticals was trading sharply lower on a jump in volume after the company said it ended a clinical trial of a late-stage pancreatic cancer drug.

SciClone Tumbles After Cancer Drug Trial Stops

SciClone Tumbles After Cancer Drug Trial Stops

SciClone Pharma shares dive after company halts trial of RP101 for pancreatic cancer

SciClone Stops Trial Of Pancreatic Cancer Drug

SciClone Stops Trial Of Pancreatic Cancer Drug

SciClone Pharma says it stopped study of cancer drug on recommendation from reviewers

Biotech Breakdown

Biotech Breakdown

Guests include Marc Lichtenfeld, senior analyst at Mt. Vernon Research, The Street.com's biotech reporter Adam Feuerstein, Breakout Stocks editor Bryan Ashenberg and Patrick Galley, portfolio manager for the RiverNorth Core Opportunity fund.

Thursday's Health Winners & Losers

Thursday's Health Winners & Losers

Bioenvision is rising.

SciClone Submits Product in China

Shares rise 14%.

Friday's Small-Cap Winners & Losers

Friday's Small-Cap Winners & Losers

SciClone soars.

SciClone Surges on Trial Data

The stock jumps more than 40%.

Monday's Health Winners & Losers

Monday's Health Winners & Losers

Allergan is up.

SciClone COO Steps Down

Friedhelm Blobel, the company's president and CEO, will take on the COO duties.

Tuesday's Health Winners & Losers

Tuesday's Health Winners & Losers

Sirna almost doubles after Merck's buyout offer.

SciClone's Outlook Gets Better

The company posts a quarterly loss that's narrower than expected.

Monday's Health Winners & Losers

Monday's Health Winners & Losers

Novogen is on the rise.

Today's Health Winners and Losers

Today's Health Winners and Losers

SciClone Pharmaceuticals jumps after its melanoma treatment gets orphan-drug status.

Today's Health Winners and Losers

Today's Health Winners and Losers

SciClone Pharmaceuticals surges after posting a narrower-than-expected loss.

Health Stocks in Motion

Health Stocks in Motion

SciClone Pharmaceuticals tumbles 41% after its hepatitis C drug fails in a late-stage trial.

Health Stocks in Motion: Possis

Health Stocks in Motion: Possis

GTC Biotherapeutics is dropping 17%.

Health Stocks in Motion

Health Stocks in Motion

Gentiva is hammered.

Health Stocks in Motion

Health Stocks in Motion

Possis Medical falls on a second-quarter earnings miss.

Sales Jump, but SciClone's IOU List Grows Faster

Sales Jump, but SciClone's IOU List Grows Faster

Some observers call the biotech's accounts-receivable trend 'a concern.'

Once-Failed Hepatitis Drug Has Some Saying SciClone's Full of Hot Air

Once-Failed Hepatitis Drug Has Some Saying SciClone's Full of Hot Air

The company boasts a market cap of $400 million, based largely on sales in less-stringent China.